PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.72%
Revenue growth similar to AVGO's 6.32%. Walter Schloss would see if both companies share industry tailwinds.
3.20%
Gross profit growth at 50-75% of AVGO's 4.96%. Martin Whitman would question if cost structure or brand is lagging.
-37.64%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-37.64%
Negative operating income growth while AVGO is at 1.00%. Joel Greenblatt would press for urgent turnaround measures.
-73.68%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-76.92%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-75.00%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.89%
Share count expansion well above AVGO's 0.15%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
-0.85%
Reduced diluted shares while AVGO is at 0.70%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-145.79%
Negative OCF growth while AVGO is at 9.32%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
32.57%
FCF growth above 1.5x AVGO's 9.56%. David Dodd would verify if the firm’s strategic investments yield superior returns.
265.26%
10Y revenue/share CAGR at 50-75% of AVGO's 416.86%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
265.26%
5Y revenue/share CAGR above 1.5x AVGO's 134.28%. David Dodd would look for consistent product or market expansions fueling outperformance.
100.39%
3Y revenue/share CAGR above 1.5x AVGO's 62.33%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-159.80%
Negative 10Y OCF/share CAGR while AVGO stands at 580.47%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-159.80%
Negative 5Y OCF/share CAGR while AVGO is at 92.77%. Joel Greenblatt would question the firm’s operational model or cost structure.
-139.81%
Negative 3Y OCF/share CAGR while AVGO stands at 39.51%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-56.29%
Negative 10Y net income/share CAGR while AVGO is at 869.72%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-56.29%
Negative 5Y net income/share CAGR while AVGO is 414.43%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-81.50%
Negative 3Y CAGR while AVGO is 16.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
647.93%
10Y equity/share CAGR at 75-90% of AVGO's 862.23%. Bill Ackman would push for either higher ROE or more earnings retention to catch the competitor.
647.93%
5Y equity/share CAGR above 1.5x AVGO's 165.61%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
128.20%
3Y equity/share CAGR at 50-75% of AVGO's 201.93%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.02%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
19.72%
Inventory growth well above AVGO's 8.08%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-18.05%
Negative asset growth while AVGO invests at 0.60%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
0.49%
Under 50% of AVGO's 5.15%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-97.28%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
11.33%
R&D growth drastically higher vs. AVGO's 13.26%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
6.28%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.